Patent ID: 11887710
Assignee: NEO7LOGIX, LLC
Field: Medical technology (Instruments)
Classification: CPC G  Y | IPC G

Claim 10:
11. A cloud-based computer system able to design a personalized peptide vaccine, comprising:
a precision based immunomolecular augmentation (PBIMA) computing platform comprising a plurality of online databases and application program interfaces (APIs), and comprising non-transitory computer readable storage medium storing computer-executable code comprising all of:
a next-generation sequencing (NGS) OMICS file processing unit comprising a Blood and RNA tumor VCF file, a WES VCF file, and a urine Proteomics data excel file;
a Peptide Analysis Tool comprising an open-source database and an online API
a Susceptibility Tool comprising an open-source database and an online API;
a Genome Uniqueness comprising an open-source database and an online API;
a Gene-Protein-Disease Interaction Database comprising an open-source or proprietary database and an online API;
a Sequence Integrity module comprising an open-source database and online API, Thermofisher, Dosorio R package);
PBIMA Unification API (Neo7Logix Cloud base integrative API) to design and rank neoantigens of the 9-aminoacid peptides-MHC-I, and 12-aminoacid peptides-MHC-II;
a Payload API to match the best payloads for delivery for a more specific targeted delivery;

a plurality of local and/or remote computers able to transmit patient input data to a PBIMA editing system, the input data comprising: NGS, WES, RNAseq, circulating DNA (ctDNA and cfDNA) and Urine proteomics data;
a wired and/or wireless network connecting local and/or remote computers' plurality;
wherein a patient has been diagnosed with, or is genetically predisposed to, a disease comprising: a cancer, an autoimmune disease, a neurodegenerative disease, or a pathogen related infectious disease; and
wherein the personalized peptide vaccine comprises a plurality of peptide sequences comprising about 5 to about 20 peptide sequences computed to be the most therapeutically effective peptide for treating the patient by eliciting a CD4+/CD8+NK cell modulation specific to a patient's profile.